Looking to sell Neumora stock or options?
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company established to tackle the global brain disease crisis through a fundamentally different approach to developing treatments for brain disorders. The company has swiftly expanded its therapeutic pipeline, which now includes seven clinical and preclinical neuroscience programs targeting novel mechanisms for a wide range of underserved neuropsychiatric and neurodegenerative conditions. Neumora plans to advance its pipeline by initiating multiple clinical trials across its programs in the next 12 to 18 months, aiming for numerous anticipated data readouts.
SoftBank Investment Advisers, Gershon Capital, Amgen, Biomatics Capital, ARCH Venture Partners.